Bio-Rad Laboratories, Inc. Class A Common Stock (BIO)
Healthcare › Laboratory Analytical Instruments
Price History
Feb 9, 2026 — May 19, 2026Investment Snapshot
- P/B of 1.11 — trading near book value
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -7.1%
Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) is a Healthcare company operating in Laboratory Analytical Instruments, listed on the NYSE , with a market capitalisation of $7.6 billion . Key value metrics: P/B ratio 1.11, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Bio-Rad Laboratories, Inc. Class A Common Stock — Fundamental Analysis Summary
On financial health, BIO shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -7.1% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.18.
StockPik's composite Value Score for BIO is 74/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BIO reports a solid gross margin of 52.5% (sector average: 40.1%) and a modest operating margin of 8.1%.
BIO shows revenue growing at 1% year-over-year, with earnings growing at 141%.